# US 2017/0281720 A1 · Peptidomimetic macrocycles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281720 A1
- Document ID: US20170281720A1
- Status: Published application
- Kind: A1
- Application number: 15/229,517
- Filed: 2016-08-05
- Published: 2017-10-05
- Earliest claimed: 2012-02-15
- Assignees: Aileron Therapeutics, Inc.
- Applicants: Aileron Therapeutics, Inc.
- Inventors: Vincent GUERLAVAIS; Carl ELKIN; Huw M. NASH; Tomi K. SAWYER; Bradford J. GRAVES; Eric FEYFANT
- Web page: https://patentgrep.com/patent/US20170281720A1

## CPC

- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/03: Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 1/113: without change of the primary structure
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 7/54: with at least one abnormal peptide link in the ring
- C07K 14/4746: {p53}
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are peptidomimetic macrocycles containing amino acid sequences with at least two modified amino acids that form an intramolecular cross-link that can help to stabilize a secondary structure of the amino acid sequence. Suitable sequences for stabilization include those with homology to the p53 protein. These sequences can bind to the MDM2 and/or MDMX proteins. Also provided herein are methods of using such macrocycles for the treatment of diseases and disorders, such as cancers or other disorders characterized by a low level or low activity of a p53 protein or high level of activity of a MDM2 and/or MDMX protein.

## Claims

### Claim at position 1

-102. (canceled)

### Claim 103

A method for treating cancer, comprising administering to a subject with cancer a therapeutically effective amount of a pharmaceutical product comprising
(a) a first therapeutic agent comprising an inhibitor of an interaction between p53 and MDM2 and/or an inhibitor of an interaction between p53 and MDMX, and
(b) a second therapeutic agent comprising a chemotherapeutic agent.

### Claim 104 (depends on 103)

The method of claim 103, wherein the first therapeutic agent and the therapeutic second agent are administered separately or as a single composition.

### Claim 105 (depends on 103)

The method of claim 103, wherein the first therapeutic agent, the second therapeutic agent, or both is administered intravenously, intraperitoneally or subcutaneously.

### Claim 106 (depends on 103)

The method of claim 103, wherein the second therapeutic agent is administered at a dosage of between 1% to 100% of a dosage of the second agent normally administered in a monotherapy regimen.

### Claim 107 (depends on 103)

The method of claim 103, wherein the cancer is selected from the group consisting of head and neck cancer, melanoma, lung cancer, breast cancer, and glioma.

### Claim 108 (depends on 103)

The method of claim 103, wherein the cancer is a hematological cancer.

### Claim 109 (depends on 103)

The method of claim 103, wherein the cancer is acute myelogenous leukemia (AML).

### Claim 110 (depends on 103)

The method of claim 103, wherein the second therapeutic agent is selected from the group consisting of a small molecule, a polypeptide, and an oligonucleotide.

### Claim 111 (depends on 103)

The method of claim 103, wherein the first therapeutic agent is a peptidomimetic macrocycle or pharmaceutically acceptable salt thereof comprising an amino acid sequence with at least about 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 10-457.

### Claim 112 (depends on 103)

The method of claim 103, wherein the first therapeutic agent is a peptidomimetic macrocycle of Formula:
or a pharmaceutically-acceptable salt thereof,
wherein:
each of Xaa3, Xaa5, Xaa6, Xaa7, Xaa8, Xaa9, and Xaa10 is independently an amino acid, wherein at least three of Xaa3, Xaa5, Xaa6, Xaa7, Xaa8, Xaa9, and Xaa10 are the same amino acids as the amino acid at the corresponding position of the sequence Phe3-X4-His5-Tyr6-Trp7-Ala8-Gln9-Leu10-X11-Ser12 (SEQ ID NO: 8) or Phe3-X4-Glu5-Tyr6-Trp7-Ala8-Gln9-Leu10/Cba10-X11-Ala12 (SEQ ID NO: 9), wherein each X4 and X11 is independently an amino acid;
each D is independently an amino acid;
each E is independently an amino acid selected from the group consisting of Ala (alanine), D-Ala (D-alanine), Aib (α-aminoisobutyric acid), Sar (N-methyl glycine), and Ser (serine);
R1 and R2 are independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-; or forms a macrocycle-forming linker L′ connected to the alpha position of one of said D or E amino acids;
L or L′ are independently a macrocycle-forming linker;
each R5 is independently halogen, alkyl, —OR6, —N(R6)2, —SR6, —SOR6, —SO2R6, —CO2R6, a fluorescent moiety, a radioisotope or a therapeutic agent;
each R6 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;
R7 is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with R5, or part of a cyclic structure with a D residue;
R8 is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with R5, or part of a cyclic structure with an E residue;
v is an integer from 1-1000; and
w is an integer from 3-1000.

### Claim 113 (depends on 112)

The method of claim 112, wherein L and L′ are independently a macrocycle-forming linker of the formula -L1-L2-;
L1 and L2 are independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, or [—R4—K—R4—]n, each being optionally substituted with R5;
each R4 is independently alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, or heterocycloalkylene; and
each K is independently O, SO, SO2, CO, CO2, or CONR3.

### Claim 114 (depends on 112)

The method of claim 112, wherein L is alkylene, alkenylene, or alkynylene.

### Claim 115 (depends on 112)

The method of claim 112, wherein R1 and R2 are independently —H or alkyl.

### Claim 116 (depends on 112)

The method of claim 112, wherein v is an integer from 2-10.

### Claim 117 (depends on 112)

The method of claim 112, wherein w is an integer from 3-10.

### Claim 118 (depends on 112)

The method of claim 112, wherein [D]v is -Leu1-Thr2.

### Claim 119 (depends on 112)

The method of claim 112, wherein each E is independently Ser or Ala.

### Claim 120

A pharmaceutical product, comprising
(a) a first therapeutic agent comprising an inhibitor of an interaction between p53 and MDM2 and/or an inhibitor of an interaction between p53 and MDM2, and
(b) a second therapeutic agent comprising a chemotherapeutic agent.

### Claim 121

A method for treating cancer, comprising administering to a subject with cancer a peptidomimetic macrocycle or pharmaceutically acceptable salt thereof comprising an amino acid sequence with at least about 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 10-457.

### Claim 122 (depends on 121)

The method of claim 121, wherein the peptidomimetic macrocycle is a peptidomimetic macrocycle of Formula:
wherein:
each of Xaa3, Xaa5, Xaa6, Xaa7, Xaa8, Xaa9, and Xaa10 is independently an amino acid, wherein at least three of Xaa3, Xaa5, Xaa6, Xaa7, Xaa8, Xaa9, and Xaa10 are the same amino acids as the amino acid at the corresponding position of the sequence Phe3-X4-His5-Tyr6-Trp7-Ala8-Gln9-Leu10-X11-Ser12 (SEQ ID NO: 8) or Phe3-X4-Glu5-Tyr6-Trp7-Ala8-Gln9-Leu10/Cba10-X11-Ala12 (SEQ ID NO: 9), wherein each X4 and X11 is independently an amino acid;
each D is independently an amino acid;
each E is independently an amino acid selected from the group consisting of Ala (alanine), D-Ala (D-alanine), Aib (α-aminoisobutyric acid), Sar (N-methyl glycine), and Ser (serine);
R1 and R2 are independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-; or forms a macrocycle-forming linker L′ connected to the alpha position of one of said D or E amino acids;
each L or L′ is independently a macrocycle-forming linker;
each R5 is independently halogen, alkyl, —OR6, —N(R6)2, —SR6, —SOR6, —SO2R6, —CO2R6, a fluorescent moiety, a radioisotope or a therapeutic agent;
each R6 is independently —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;
R7 is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with R5, or part of a cyclic structure with a D residue;
R8 is —H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with R5, or part of a cyclic structure with an E residue;
v is an integer from 1-1000; and
w is an integer from 3-1000.
